Navigation Links
Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
Date:7/9/2012

SAN DIEGO, July 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Thursday, July 12th at 3:00 p.m. EDT. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

WCG(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
8. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/28/2020)... ... , ... On January 8, Upshoot kicked off its inaugural 2020 Community Reboot ... nutrition, 10 days at a time. The healthy lifestyle brand’s ‘New Year, New Yoú’ ... 1, and leveraged the power of social community to support people in achieving their ...
(Date:1/28/2020)... ... January 28, 2020 , ... Heather Furnas, MD FACS ... CoolTone body contouring device. This brand new offering from the makers of ... Surgery Associates’ Santa Rosa office will begin CoolTone consultations in late December, with ...
(Date:1/28/2020)... ... , ... With camaraderie and community at the heart of its services, Calusa ... drug and alcohol rehab center, it offers plush surroundings and a range of additional ... psychoeducational groups, Calusa is treating the entire person rather than just focusing on one ...
Breaking Medicine Technology:
(Date:1/24/2020)... ... January 24, 2020 , ... ... firm for the life sciences and food industries, is pleased to announce that ... their head office and research site in Toronto, Canada. , Dr. Assadi’s extensive ...
(Date:1/23/2020)... Calif. (PRWEB) , ... January 23, 2020 , ... A ... chins and options to get rid of them. The article quotes the president of ... call a double-chin are many. They can be caused by a person’s facial structure ...
(Date:1/23/2020)... HUNTINGTON BEACH, Calif. (PRWEB) , ... January 23, 2020 , ... ... weaknesses in family dynamics came out strongly. Old family issues, rivalries, and secrets were ... holidays altogether. For many of those coping with addiction and their families, the holidays ...
(Date:1/23/2020)... ... 23, 2020 , ... Park Avenue based orthopedic surgeon Dr. Jeffrey Schildhorn ... to bring this new digital portal for patient education to his existing and future ... Temple University. With over 12 years of hands-on experience, Dr. Schildhorn has built his ...
(Date:1/23/2020)... ... January 23, 2020 , ... Relatient, ... Healthpac, a trusted medical billing software company for revenue cycle management (RCM) ... Healthpac’s customers can now access Relatient's latest solutions to improve the patient's ...
Breaking Medicine News(10 mins):